SEC Form 4 · accession 0002074701-26-000005
Outlook Therapeutics, Inc. · OTLK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kevin Michael Lundquist
Officer — Chief Financial Officer
Period of report
Sep 1, 2026
Accepted (ET)
Sep 2, 2026 · 4:32 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001649989
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $0.63 | Sep 1, 2026 | A | 500,000 | A | — | Sep 1, 2036 | Common Stock | 500,000 | 500,000 | D |
Explanation of responses
- F1The option was granted by Outlook Therapeutics, Inc. (the "Issuer") as an inducement material to the Reporting Person's entry into employment with the Issuer in accordance with Nasdaq Listing Rule 5635(c)(4). 25% of the shares subject to the option shall vest on September 1, 2027, with the remaining shares vesting in equal monthly installments over the following three years thereafter, subject to the Reporting Person's continuous service with the Issuer on each such date.